Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin in Progressive Multiple Sclerosis
NCT05349474Phase 1Completed
- Sponsor
- University of California, Los Angeles
- Start
- Apr 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of liquid metformin (Aspargo Labs) in primary progressive multiple sclerosis (PPMS) and Secondary Progressive Multiple Sclerosis (SPMS), sponsored by University of California, Los Angeles. Primary endpoints: Number of patients with adverse events at 12 months and Number of patients with laboratory abnormalities at 12 months. Started Apr 2022; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
primary progressive multiple sclerosis (PPMS)Secondary Progressive Multiple Sclerosis (SPMS)
Beyond the preview
Go deeper on NCT05349474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05349474.